Diagnostics: Key Developments in Technologies and Markets addresses
the latest trends and developments in cardiovascular imaging and
in vitro diagnostic techniques that will impact the market and
the delivery of healthcare.
Cardiovascular diseases continue to be an enormous medical and
cost burden on the health care system. As the rapidly aging population
drives an increase in the incidence and prevalence of heart disease,
the need for early detection and intervention will escalate dramatically.
Cardiovascular Diagnostics: Key Developments
in Technologies and Markets describes how the evolution of imaging technologies
and discovery of new biomarkers is leading to continuous improvement
in the ability to diagnose disease, monitor drug treatment, and
identify patients at risk for cardiovascular events, such as
heart attack and stroke.
The following market trends and developments, as well as the
companies competing in each area, are evaluated:
- A high clinical need exists for non-invasive angiography
procedures to assess coronary artery blockages. The report evaluates
new CT scan technology and its potential to deliver billions
of dollars in savings to the health care system along with a
lower risk of complications for the patient.
cardiovascular biomarkers that will allow for better detection
of patients at risk for developing coronary
artery disease, including C-Reactive Protein, as well as a number
of different inflammatory and ischemia biomarkers that are under
investigation for faster diagnosis of myocardial infarction and
to rule out acute coronary syndrome in patients presenting with
- New radiopharmaceuticals agents being developed
for cardiovascular nuclear medicine that promise to improve diagnosis.
in magnetic resonance (MR) imaging and other imaging modalities
used in cardiovascular diagnostics.
- Early-stage developments
in imaging unstable or ruptured plaque deposits in arteries.
emerging trend of cardio-theranostics, the pairing of a laboratory
test with a cardiovascular drug.
Alberto Abate, bioMérieux; Kenneth F. Buechler, PhD,
Biosite; Hans-Juergen Loyda, Roche
Diagnostics; David Ludvigson, Nanogen, Inc.; James Kronauge,
PhD, Molecular Insight; Gregg
Mayer, EPIX Pharmaceuticals